Tandem Diabetes Care (NSDQ:TNDM) said today that it plans to use its remote software update tool to address an anomaly found in an ongoing pivotal trial of its Control-IQ technology.
The anomaly, according to Tandem, relates to how the company’s t:slim X2 insulin pump with Control-IQ technology handles continuous glucose monitoring data under undisclosed conditions. The company reported that the anomaly could impact the system’s prediction of future blood glucose values and automated insulin delivery.
Get the full story at our sister site, Drug Delivery Business News.
The post Tandem addresses anomaly in pivotal trial for closed-loop tech appeared first on MassDevice.